---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-026757"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T11:20:26.850349+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corcept Q2 revenue $117.7M (+14% YoY); raises FY revenue guidance to $455-470M

## Summary
- Revenue $117.7M, up 14% YoY; net income $27.5M ($0.25 diluted EPS) vs $27.4M ($0.24) in Q2 2022.
- Raises FY 2023 revenue guidance to $455-470M from $435-455M; cash $363.3M.
- Repurchased 6.6M shares for $145.4M in April 2023.
- Clinical: GRACE Phase 3 enrollment complete; relacorilant NDA submission expected Q2 2024.
- ROSELLA ovarian cancer trial enrollment on track to complete by end of 2023; Phase 2b NASH trial to start Q4 2023.

## SEC filing metadata
- accession: 0001628280-23-026757
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828023026757/0001628280-23-026757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828023026757/cort-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-026757
- JSON: https://secwatch.observer/filing/0001628280-23-026757.json
- Plain text: https://secwatch.observer/filing/0001628280-23-026757.txt

## Key facts
- Earnings Releases
  CORCEPT THERAPEUTICS INC reported the quarter ended June 30, 2023 results: revenue $117.7 million, net income $27.5 million, EPS $0.25 (diluted). Guidance raised.
  - Period: the quarter ended June 30, 2023
  - Revenue: $117.7 million
  - Net income: $27.5 million
  - EPS: $0.25 (diluted)
  - Guidance: raised
  - Result: reported results
  source text: metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended June 30, 2023. Financial Results • Revenue of $117.7 million, a 14 percent increase from second quarter 2022 • Increase in 2023 revenue guidance to $455 – $470 million, from $435 – $455 million • Net income per common share of $0.25
  evidence_url: https://www.sec.gov/Archives/edgar/data/1088856/000162828023026757/0001628280-23-026757-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.